Increlex Treatment of Children With Chronic Liver Disease and Short Stature
| Tracking Information | |
|---|---|
| First Received Date ICMJE | March 8, 2011 |
| Last Updated Date | March 23, 2011 |
| Start Date ICMJE | June 2011 |
| Estimated Primary Completion Date | June 2013 (final data collection date for primary outcome measure) |
| Current Primary Outcome Measures ICMJE |
Growth velocity is the primary outcome. Improved height SDS [ Time Frame: One year of therapy ] [ Designated as safety issue: No ] Improved growth velocity with improved height standard deviation scores (SDS) is the primary expected result. |
| Original Primary Outcome Measures ICMJE |
Growth velocity is the primary outcome. Improved height SDS [ Time Frame: One year of therapy ] [ Designated as safety issue: No ] Improved growth velocity with improved height standard deviation scores (SDS) is the primary exoected resykt. |
| Change History | Complete list of historical versions of study NCT01314508 on ClinicalTrials.gov Archive Site |
| Current Secondary Outcome Measures ICMJE |
|
| Original Secondary Outcome Measures ICMJE | Same as current |
| Current Other Outcome Measures ICMJE | Not Provided |
| Original Other Outcome Measures ICMJE | Not Provided |
| Descriptive Information | |
| Brief Title ICMJE | Increlex Treatment of Children With Chronic Liver Disease and Short Stature |
| Official Title ICMJE | Increlex Treatment of Children With Chronic Liver Disease and Short Stature |
| Brief Summary | A major consequence of chronic liver disease in childhood is growth failure. This is because a chemical essential for growth called growth factor is created in the liver. Lack of response to growth hormone in people with chronic liver disease is characterized by high levels of growth hormone and low levels of growth factors. This growth hormone resistance is reflected in a variety of factors including insulin resistance and low nutritional intake. Unfortunately, growth hormone therapy has no effect for children with liver disease. In addition, failure of normal growth or malnutrition makes liver disease even worse in children, and growth hormone therapy is not likely to reverse this. A lack of proper nutrition is associated with hospitalizations and frequent complications. Poor growth is a predictor of poor outcomes after liver transplantation. Thus the management of children with liver disease remains a challenge. Children who have successful orthotopic liver transplants (OLT) show much improvement in some aspects of growth, including skin fold thickness, mid-arm circumference, and normalization of growth factor levels. However, some studies have recently reported that the growth of 15-20% of children remains poor even after a liver transplant. This can be explained by persistent abnormalities in growth factors after transplant. Growth factor was found to be a good tool for prognosis in patients with chronic liver disease. Studies showed that patients with liver cirrhosis and growth factor levels below normal values showed lower long-term survival rates compared with patients who had above normal values. This suggests that growth factor can be a good predictor of survival and early marker of poor liver function. In this case, aggressive feeding may modestly improve growth factor levels leading to improved growth but it is unlikely that effects will be optimal. The investigators propose that growth factor administration may have a positive effect that leads to better growth which is a major predictor of good outcome. To date, no reports study the use of growth factor in children with chronic liver disease. This study proposes to examine the effect of growth factor therapy in childhood chronic liver disease. |
| Detailed Description | Not Provided |
| Study Type ICMJE | Interventional |
| Study Phase | Not Provided |
| Study Design ICMJE | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Condition ICMJE |
|
| Intervention ICMJE | Drug: Increlex
Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week. |
| Study Arm (s) | All patients will be treated with IGF-1 factors
Patients will serve as their own control.
Intervention: Drug: Increlex |
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Recruitment Status ICMJE | Not yet recruiting |
| Estimated Enrollment ICMJE | 20 |
| Completion Date | Not Provided |
| Estimated Primary Completion Date | June 2013 (final data collection date for primary outcome measure) |
| Eligibility Criteria ICMJE | Inclusion Criteria: Pre liver transplant patients with:
Exclusion Criteria:
|
| Gender | Both |
| Ages | 4 Years to 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts ICMJE | Not Provided |
| Location Countries ICMJE | Not Provided |
| Administrative Information | |
| NCT Number ICMJE | NCT01314508 |
| Other Study ID Numbers ICMJE | 07-03-018 |
| Has Data Monitoring Committee | No |
| Responsible Party | Anna Haddal, M.D., UCLA Department of Pediatrics, Division of Pediatric Endocrinology |
| Study Sponsor ICMJE | University of California, Los Angeles |
| Collaborators ICMJE | Not Provided |
| Investigators ICMJE | Not Provided |
| Information Provided By | University of California, Los Angeles |
| Verification Date | February 2011 |
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|